A Double-Blind, Randomized, Parallel, Two-Arm Phase H Trial of BMS-690514 versus Erlotinib in Previous Chemotherapy-Treated Non-small Cell Lung Cancer (NSCLC) Patients: A Safety Review

被引：0
|
作者：
Sbar, E. [1 ]
Besse, B. [2 ]
Felip, E. [3 ]
Shaw, A. [4 ]
Ahn, M. [5 ]
Salvati, M. [1 ]
Bhagavatheeswaran, P. [1 ]
Soria, J. [2 ]
机构：
[1] Bristol Myers Squibb Co, Princeton, NJ USA
[2] Inst Gustave Roussy, Villejuif, France
[3] Hosp Valle De Hebron, Barcelona, Spain
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
[5] Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2010年 / 5卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S538 / S539
页数：2
相关论文
共 50 条
  • [1] A Double-Blind, Randomized, Parallel, Two-Arm Phase II Trial of BMS-690514 versus Erlotimb in Previous Chemotherapy-Treated Non-Small Cell Lung Cancer (NSCLC) Patients A Safety Review
    Sbar, Eric
    Besse, Benjamin
    Felip, Enriqueta
    Shaw, Alice
    Ahn, Myung-Ju
    Salvati, Mark
    Bhagavatheeswaran, Prabhu
    Soria, Jean-Charles
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S385 - S385
  • [2] Vandetanib versus erlotinib in patients with previously treated advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial
    Goss, G. D.
    Thongprasert, S.
    Greco, F. A.
    Thomas, M.
    Tsai, C. M.
    Sunpaweravong, P.
    Ferry, D.
    Gogov, S.
    Rowbottom, J. A.
    Natale, R. B.
    EJC SUPPLEMENTS, 2009, 7 (02): : 506 - 506
  • [3] Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514
    Bahleda, R.
    Soria, J.
    Harbison, C.
    Park, J.
    Felip, E.
    Hanna, N.
    Laurie, S. A.
    Armand, J.
    Shepherd, F. A.
    Herbst, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] A RANDOMIZED, DOUBLE-BLIND PHASE III STUDY OF ICOTINIB VERSUS GEFITINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PREVIOUSLY TREATED WITH CHEMOTHERAPY (ICOGEN)
    Sun, Yan
    Shi, Yankai
    Zhang, Li
    Liu, Xiaoqing
    Zhou, Caicun
    Zhang, Li
    Wang, Dong
    Li, Qiang
    Zhang, Shucai
    Qin, Shukui
    Hu, Chunhong
    Zhang, Yiping
    Tan, Fenlai
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S317 - S318
  • [5] A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN)
    Sun, Y.
    Shi, Y.
    Zhang, L.
    Liu, X.
    Zhou, C.
    Zhang, L.
    Wang, D.
    Li, Q.
    Zhang, S.
    Qin, S.
    Hu, C.
    Zhang, Y.
    Chen, J.
    Song, Y.
    Feng, J. F.
    Cheng, Y.
    Zhang, H.
    Wu, Y. L.
    Xu, N.
    Zhou, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST)
    Natale, R. B.
    Thongprasert, S.
    Greco, F. A.
    Thomas, M.
    Tsai, C. M.
    Sunpaweravong, P.
    Ferry, D.
    Langmuir, P.
    Rowbottom, J. A.
    Goss, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial
    Gogishvili, Miranda
    Melkadze, Tamar
    Makharadze, Tamta
    Giorgadze, Davit
    Dvorkin, Mikhail
    Penkov, Konstantin
    Laktionov, Konstantin
    Nemsadze, Gia
    Nechaeva, Marina
    Rozhkova, Irina
    Kalinka, Ewa
    Gessner, Christian
    Moreno-Jaime, Brizio
    Passalacqua, Rodolfo
    Li, Siyu
    McGuire, Kristina
    Kaul, Manika
    Paccaly, Anne
    Quek, Ruben G. W.
    Gao, Bo
    Seebach, Frank
    Weinreich, David M.
    Yancopoulos, George D.
    Lowy, Israel
    Gullo, Giuseppe
    Rietschel, Petra
    NATURE MEDICINE, 2022, 28 (11) : 2374 - +
  • [8] Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial
    Miranda Gogishvili
    Tamar Melkadze
    Tamta Makharadze
    Davit Giorgadze
    Mikhail Dvorkin
    Konstantin Penkov
    Konstantin Laktionov
    Gia Nemsadze
    Marina Nechaeva
    Irina Rozhkova
    Ewa Kalinka
    Christian Gessner
    Brizio Moreno-Jaime
    Rodolfo Passalacqua
    Siyu Li
    Kristina McGuire
    Manika Kaul
    Anne Paccaly
    Ruben G. W. Quek
    Bo Gao
    Frank Seebach
    David M. Weinreich
    George D. Yancopoulos
    Israel Lowy
    Giuseppe Gullo
    Petra Rietschel
    Nature Medicine, 2022, 28 : 2374 - 2380
  • [9] Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)
    Tran, Hai T.
    Zinner, Ralph G.
    Blumenschein, George R., Jr.
    Oh, Yun W.
    Papadimitrakopoulou, Vassiliki A.
    Kim, Edward S.
    Lu, Charles
    Malik, Mubashira
    Lum, Bert L.
    Herbst, Roy S.
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (03) : 499 - 505
  • [10] Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)
    Hai T. Tran
    Ralph G. Zinner
    George R. Blumenschein
    Yun W. Oh
    Vassiliki A. Papadimitrakopoulou
    Edward S. Kim
    Charles Lu
    Mubashira Malik
    Bert L. Lum
    Roy S. Herbst
    Investigational New Drugs, 2011, 29 : 499 - 505
12345